Smith J L, de Jersey J, Pillay S P, Hardie I R
Clin Chim Acta. 1986 Aug 15;158(3):271-82. doi: 10.1016/0009-8981(86)90291-3.
A standard assay was developed for human liver acyl-CoA:cholesterol acyltransferase (ACAT, EC 2.3.2.26) which is more sensitive than previous methods and allows accurate activity determinations on crude microsomal fractions. ACAT activity was measured in microsomes from livers of four gallstone patients and five controls. Preincubation with exogenous cholesterol produced an increase in ACAT activity in all liver samples: gallstone samples showed a mean increase of 1.8-fold, whereas non-gallstone samples showed a mean increase of 8.2-fold. The mean ACAT activity measured in the presence of exogenous cholesterol was 52.8 +/- 22.8 (n = 4) pmol . min-1 . mg-1 for gallstone samples and 82.8 +/- 13.5 (n = 4) pmol . min-1 . mg-1 for non-gallstone samples. These results suggest that patients suffering from cholesterol gallstones have a reduced ability to esterify potentially harmful free cholesterol compared with controls. They support the proposition that cholesterol gallstone formation is related to altered hepatic cholesterol metabolism.
开发了一种用于人肝脏酰基辅酶A：胆固醇酰基转移酶（ACAT，EC 2.3.2.26）的标准检测方法，该方法比以前的方法更灵敏，能够对粗微粒体组分进行准确的活性测定。测定了4例胆结石患者和5例对照者肝脏微粒体中的ACAT活性。用外源性胆固醇进行预孵育后，所有肝脏样本中的ACAT活性均增加：胆结石样本平均增加1.8倍，而非胆结石样本平均增加8.2倍。在存在外源性胆固醇的情况下测定的胆结石样本的平均ACAT活性为52.8±22.8（n = 4）pmol·min-1·mg-1，非胆结石样本为82.8±13.5（n = 4）pmol·min-1·mg-1。这些结果表明，与对照相比，胆固醇胆结石患者酯化潜在有害游离胆固醇的能力降低。它们支持胆固醇胆结石形成与肝脏胆固醇代谢改变有关的观点。
